Exposure Clinical Trial
Official title:
A First In Human, Single Blind, Placebo Controlled, Randomized Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SP-333 Tablets in Healthy Adult Subjects
NCT number | NCT01705938 |
Other study ID # | SP333101 |
Secondary ID | |
Status | Completed |
Phase | Phase 1 |
First received | |
Last updated | |
Start date | October 2012 |
Est. completion date | December 2012 |
Verified date | May 2019 |
Source | Bausch Health Americas, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a randomized, phase 1, single-blind, placebo-controlled, randomized, sequential, escalating, single-dose, study designed to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) properties of orally administered SP-333 tablets.
Status | Completed |
Enrollment | 56 |
Est. completion date | December 2012 |
Est. primary completion date | December 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: 1. Male or female subjects between 18 and 55 years old 2. Body weight greater than or equal to 50 kg (110 pounds) and Body Mass Index (BMI) in the range of 18 to 30 kg/ m2 3. Medically healthy with no clinically significant findings. 4. Subjects must have bowel habits that are considered regular (for this study a minimum of 4 bowel movements a week without laxatives). 5. Subject must have had a bowel movement, without laxatives, in the 3 days before administration of study drug. 6. Male subjects with female sexual partners of child-bearing potential must agree to use highly effective contraceptive methods during the study. 7. Female subjects must be post-menopausal and not pregnant. 8. Subjects must understand and agree to comply with the requirements of the study and they must be willing to sign an Informed Consent Form. Exclusion Criteria: 1. Smokers or users of nicotine products who do not agree to not smoke or use nicotine products during their stay in the CPU. 2. Current or history of clinically significant diseases, including gastrointestinal, renal, hepatic, neurologic (e.g., neuropathy), hematologic, endocrine (e.g., diabetes), oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease or any other condition. 3. Presence of any abnormal clinically significant laboratory. 4. History of any serious allergic reaction to any medication 5. Certain abnormalities of the ECG. 6. Participated in a previous clinical study with an investigational product within 30 days of study Participation 7. Donated blood, blood components or significant loss of blood within 2 months of dosing 8. History of a clinically-significant illness within 4 weeks of dosing 9. Special diet, any dietary habits, or restrictions, which, may interfere with conduct of the study or health of the subject within 30 days of dosing 10. History of clinically-significant drug or alcohol abuse within 2 years of study participation 11. Positive urine screen for prohibited drugs (cocaine, cannabinoids, opiates, barbiturates, amphetamines, benzodiazepines, phencyclidine, propoxyphene). 12. History of human immunodeficiency virus (HIV), hepatitis B surface antigen positive (+HBsAg), or hepatitis C antibody positive (+HCVAb). 13. History of certain surgeries: - Gastric bypass surgery or invasive procedure for the treatment of obesity or surgery to remove a segment of the gastrointestinal (GI) tract at any time. - Patients who have had a gastric band (unless the band has been completely removed for more than 60 days) - Surgery of the abdomen, pelvis or retroperitoneal structures within six months of study participation. - Appendectomy,Instrumentation of the bowel, major surgery within 60 days of study participation. 14. Female subjects of childbearing potential or who are breastfeeding 15. Use of any routine systemic medication, including any over the counter (OTC) medication within 2 weeks of dosing 16. Use of herbal products, dietary supplements, vitamins, grapefruit, or grapefruit containing products within 2 weeks of dosing 17. Irregular daily bowel habits 18. Any other issue which, in the judgment of the investigator, will make the subject ineligible for study participation |
Country | Name | City | State |
---|---|---|---|
United States | Anaheim Clinical Trials | Anaheim | California |
Lead Sponsor | Collaborator |
---|---|
Bausch Health Americas, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of participants with treatment emergent adverse events as a measure of safety and tolerability | 14 days | ||
Secondary | Area under the plasma concentration versus time curve (AUC) of SP-333 following single oral doses of tablets. | 48 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04109677 -
AIM CONTROL and SWECON - Handball The SWEdish CONcussion Study in Elite Handball
|
||
Not yet recruiting |
NCT04919434 -
Intervention to Reduce Exposure to Environmental COntaminant (IRECO)
|
N/A | |
Completed |
NCT04064255 -
Evaluation of Practical Body Image Therapy for Anorexia Nervosa V1
|
N/A | |
Completed |
NCT01450969 -
New Fabric Attenuation Device in Endovascular Interventional Radiology (PREFER)
|
N/A | |
Completed |
NCT05128981 -
Internet-delivered Cognitive Behavioral Therapy Following Myocardial Infarction
|
N/A | |
Completed |
NCT03712748 -
Online Imaginal Exposure
|
N/A | |
Recruiting |
NCT04297462 -
Different Regimens in Influenza Postexposure Chemoprophylaxis in Children
|
N/A | |
Completed |
NCT05322655 -
PAthogen Transmission and Health Outcome Models of Enteric Disease
|
||
Completed |
NCT05158010 -
Advancing Tools for Human Early Lifecourse Exposome Research and Translation- Adolescence Follow-up of the HELIX Subcohort
|
N/A | |
Recruiting |
NCT06208202 -
Perceptions of E-Cigarettes and Synthetic Cooling Agents, The ICE Study
|
N/A | |
Recruiting |
NCT05079984 -
Agile Development of a Digital Exposure Treatment for Youth With Chronic Musculoskeletal Pain
|
N/A | |
Completed |
NCT01365988 -
Neutral Correlates of Risk-taking in Adolescents Exposed to Drugs Prenatally
|
||
Completed |
NCT03934697 -
Imaginal Exposure II Study: In-Vivo
|
N/A | |
Completed |
NCT01087307 -
Sample Collection Registry for Quality Control of Biological and Environmental Specimens and Assay Development and Testing
|
||
Recruiting |
NCT05869747 -
Firefighter Collaborative Research Project
|
N/A | |
Completed |
NCT03414801 -
Red Maple Trials Cat Allergen Natural Exposure Chamber Validation in Cat-allergic Subjects
|
N/A | |
Completed |
NCT02199535 -
The Analysis of the Risks of the Personnel Working in Anesthesiology Departments in Turkey
|
N/A | |
Not yet recruiting |
NCT06338800 -
One Session Virtual Reality During Ongoing Treatment for Anxiety: Feasibility in Children and Adolescents
|
N/A | |
Not yet recruiting |
NCT06323538 -
Cohort Study on Plant-based Diets (COPLANT Study)
|